Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

15 results about "Suicide gene" patented technology

A suicide gene, in genetics, will cause a cell to kill itself through apoptosis. Activation of these genes can be due to many processes, but the main cellular "switch" to induce apoptosis is the p53 protein. Stimulation or introduction (through gene therapy) of suicide genes is a potential way of treating cancer or other proliferative diseases. Suicide genes form the basis of a strategy for making cancer cells more vulnerable, more sensitive to chemotherapy. The approach has been to attach parts of genes expressed in cancer cells to other genes for enzymes not found in mammals that can convert a harmless substance into one that is toxic to the tumor. Most suicide genes mediate this sensitivity by coding for viral or bacterial enzymes that convert an inactive drug into toxic antimetabolites that inhibit the synthesis of nucleic acid. Suicide genes must be introduced into the cells in ways that ensure their uptake and expression by as many cancer cells as possible, while limiting their expression by normal cells. Suicide gene therapy for cancer requires the vector to have the capacity to discriminate between target and non target cells, between the cancer cells and normal cells.

Novel screening system for activators and inhibitors of signaling pathways based on cell death and life phenotypes

This invention provides a novel screening method for signaling pathway activators and inhibitors based on cell viability / death phenotypes. Specifically, this invention provides genetically engineered cells that enable large-scale screening of signaling pathway activators and inhibitors based on the expression of protective and suicide genes driven by signaling pathway transcription factors. The viability / death phenotype reporter system is effective and convenient for screening drugs affecting signaling pathways and can be applied to high-throughput screening in the early stages of drug development.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Methods and compositions for selectively eliminating cells of interest

The present disclosure provides novel compositions and methods suitable for specifically eliminating target cells (e.g., cancer cells) without affecting non-target cells (e.g., non-cancer cells). For example, CRISPR system and the compositions of the present disclosure can be employed to specifically introduce a suicidal gene into a cancer cell in the loci of a cancer-specific target sequence, which as a result of chromosomal re-arrangement or translocation in a cancer cell presents a cancer specific sequence for a guide RNA and CAS to be recognized and such sequence is absent in a non-cancer cell. Consequently, the specific introduction of the composition(s) to cancer-specific site(s) and integration of suicide gene in the target genome, which is inapplicable to normal cells for lack of the site(s), leads to selective elimination of cancer cells but not non-cancer cells, and therefore render novel therapeutic methods and compositions for cancer treatment.
Owner:ZHU JAMES

HLA class I MHC cell excision

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).
Owner:AZTHERAPIES INC

Armored chimeric antigen receptor t cells

The present application relates to sequences for expression in engineered chimeric antigen receptor (CAR) T cells for targeting IL13Ra2. In some embodiments, the sequences include a humanized VHH binder specific to IL13Ra2, an intracellular signaling domain, armoring elements to support cell persistence and functionality, or any combination thereof. Also disclosed herein are T cells that include a suicide gene for controlled cell elimination, and therapeutic uses thereof.
Owner:CHIMERIS UK LTD +1

Her2-based suicide switch

The present application relates to a suicide gene system and its use as part of immunotherapy. In some embodiments, the suicide gene system is expressed in a CAR T-cell, optionally along with armoring proteins. The present application also discloses uses of the suicide gene system, such as in cell tracking, immune regulation, rapid elimination of CAR T-cells, and as part of a therapeutic treatment.
Owner:CHIMERIS UK LTD +1

CASP9 suicide gene safety switch controlled by teton system and construction thereof

PCT designated stageWO2026002063A1HydrolasesMammal material medical ingredientsDimerT-cell apoptosis
The present invention provides a CASP9 suicide gene safety switch controlled by a TetOn system and construction thereof. Specifically, the present invention provides a coiled coil-CASP9 fusion protein whose expression is regulated by a tetracycline-inducible system. A dimer or multimer is formed by means of a coiled-coil sequence, so that Caspase-9 has cleavage activity, thereby inducing CAR-T cell apoptosis. The present invention has the effects of reducing adverse reactions and improving safety during CAR-T therapy.
Owner:XUZHOU MEDICAL UNIVERSITY

Safe and controllable chimeric antigen receptor loaded with suicide gene, macrophages expressing same and application thereof

The application uses gene editing technology to design and optimize a safe and controllable chimeric antigen receptor loaded with a suicide gene, and a macrophage expressing the same, the chimeric antigen receptor comprising a single-chain variable region targeting carcinoembryonic antigen (CEA), a hinge region, a transmembrane region, and an intracellular signaling region. The application has the following advantages: the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has high infiltration, enhanced phagocytosis and antigen presentation capacity, and is expected to become a new strategy for the immunotherapy of solid tumor cells. The constructed stem progenitor cells proliferate rapidly, can be obtained in large quantities in a short time, and can be frozen for long-term preservation. The induction of macrophages is short, simple and convenient, the macrophages efficiently express CAR, are stable and uniform, small molecule compounds regulate the fate of progenitor cells and macrophages, are safe and controllable, and have an anti-colorectal cancer treatment effect. The CAR-Hoxb8-M combined with an immune checkpoint inhibitor can further inhibit tumor growth and improve survival rate.
Owner:NANJING UNIV

Engineering suicide gene approaches to improve chemotherapeutic response in cancer

Disclosed are compositions and methods for treating a disease and / or disorder such as cancer in a subject in need thereof. In some embodiments, the method includes administering to the subject a nucleic acid construct that includes a first nucleic acid sequence having a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by stress-activated kinase activity in a target cell and / or tissue. In some embodiments, the target cell and / or tissue is a cell and / or tissue undergoing a stress response. In some embodiments, the kinase activity is stress-activated kinase activity mediated by p38 / MAP14 kinase activity, INK activity, or both.
Owner:UNIV OF VIRGINIA PATENT FOUND

Engineered immune cells expressing a car and a plurality of protein expression blockers and uses thereof

The present invention provides one or more expression vectors encoding one or more of an anti-CD7 chimeric antigen receptor (CAR), an anti-CD7 protein expression blocker, a kill gene or a suicide gene, and an anti-CD3 protein expression blocker. Also provided are immune cells comprising the one or more expression vectors. Also provided are methods of producing such one or more expression vectors or immune cells. Also provided are methods of using such one or more expression vectors or immune cells for treating cancer while reducing symptoms of Graft-versus-host disease (GvHD).
Owner:IASO BIOTHERAPEUTICS USA LTD

Gene therapeutic vector for KSHV-associated diseases

PCT designated stageWO2026055462A1VectorsPeptide/protein ingredientsDiseaseMalignancy
Disclosed are compositions and methods for the treatment of KSHV-infected malignancies through administering an AAV gene therapy vector. The AAV vector encodes two copies of the TR sequence, a gene promoter and a suicide gene. The gene therapy vector leads to tumor cell apoptosis and further reactivation of KSHV transactivator to further activate therapeutic genes.
Owner:RGT UNIV OF CALIFORNIA

DNA, expression vector, transcript, cell, pharmaceutical composition, and medicine

An object of the invention is to provide a novel pharmaceutical composition. The pharmaceutical composition of the disclosure contains a DNA encoding a suicide gene having at least one intron sequence. The intron sequence has a donor sequence or an acceptor sequence to be used in a tumor cell with abnormal splicing not in a normal cell. In a transcript of the DNA, the suicide gene is expressed when the intron is abnormally spliced and the suicide gene is not expressed when the intron is not abnormally spliced.
Owner:HITACHI LTD

CASP9 suicide gene safety switch controlled by TetOn system and construction thereof

PendingCN121227805AHydrolasesMammal material medical ingredientsDimerT-cell apoptosis
The invention provides a CASP9 suicide gene safety switch controlled by a TetOn system and construction of the CASP9 suicide gene safety switch. Specifically, the invention provides a coiled helic-CASP9 fusion protein regulated and expressed by a tetracycline induction system, and a dimer or multimer is formed through a coiled helical sequence, so that Caspase-9 has cleavage activity so as to induce CAR-T cell apoptosis. The invention has the efficacy of reducing adverse reaction and improving safety in the process of CAR-T therapy.
Owner:XUZHOU MEDICAL UNIVERSITY

Compositions comprising a tweak ligand and methods of using same

ActiveUS12714740B2NanoparticleTumor necrosis factor receptor
The instant disclosure relates to nanoparticle compositions that may be used for the targeting of certain cells or tissues. The nanoparticles may take a variety of different forms, including non-viral, viral, and lipid nanoparticles, and may utilize a TNF receptor superfamily member 12A (“TWEAKR”) binding region of the TWEAK protein to target a nanoparticle to tissues expressing TWEAKR. The compositions may further comprise a suicide gene optionally under the control of a tissue specific promoter. In further aspects, methods of treating an individual using the disclosed nanoparticle compositions are described.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +2

Secreted RNA therapeutics for nuclear delivery

Disclosed herein is a system that addresses the current challenges described by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. The system generally involves a first poly nucleotide encoding retroviral elements that preferentially binds and facilitates formation and secretion of vesicles carrying its own RNA messenger operably linked to a first expression control sequence; a second polynucleotide encoding an RNA therapeutic having a nuclear retention sequence that is flanked by packaging signals for the retroviral elements operably linked to a second expression control sequence; and a third polynucleotide encoding a membrane fusion protein operably linked to a third expression control sequence.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Gene diagnosis and treatment system for tumors and preparation method of gene diagnosis and treatment system

The invention provides a gene diagnosis and treatment system for tumors. The gene diagnosis and treatment system comprises a PEG3 gene, an FTH1 gene and an HSV-TK gene which are connected in sequence to form PEG3-FTH1-HSV-tk. The diagnosis and treatment integrated system provided by the invention can realize the diagnosis and treatment of tumors more quickly and effectively at the same time. According to the non-invasive imaging method for diagnosing by using the magnetic resonance reporter gene for imaging, the burden of a child patient is reduced, tumor cells and tissues are killed by using the suicide gene during diagnosis, and the neuroblastoma is treated by using gene therapy, so that diagnosis and treatment can be realized at the same time.
Owner:CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV